Articles

Highlights in immunotherapy

BJMO - volume 15, issue 5, september 2021

B. Neyns MD, PhD

Over the last decade immunotherapy has become an integral part of the oncogenic treatment arsenal. Meanwhile, the field of immune-oncology continues to evolve, which was amply illustrated by the large number of studies evaluating innovative immunotherapies presented at ASCO 2021.

(BELG J MED ONCOL 2021;15(5):218-23)

Read more

Highlights in melanoma

BJMO - volume 14, issue 8, december 2020

J. Blokken PhD, PharmD, Tom Feys MBA, MSc, B. Neyns MD, PhD

At ESMO 2020, most attention in the melanoma field went to studies addressing the benefit of immunotherapy, alone or in combination with other drugs. First of all, updates on the use of immunotherapy in the adjuvant setting were provided for the Keynote-054 and the CheckMate 238 trials. In the advanced melanoma setting, several studies investigating combinations of immunotherapy with targeted agents will be addressed. In addition to this, the ILLUMINATE-204 trial investigates the potential of combining immunotherapy with intratumoral therapy. Similarly, a second study describes the value of local therapy in the treatment of solitary melanoma after progression upon checkpoint inhibitors. Finally, vaccination strategies with an IDO/ PD-L1 peptide vaccine and adjuvant dendritic cell vaccination will be discussed.

Read more

Highlights in melanoma

BJMO - volume 14, issue 5, september 2020

J. Blokken PhD, PharmD, Tom Feys MBA, MSc, B. Neyns MD, PhD

Summary

Over the last decade, the treatment of advanced melanoma underwent a dramatic improvement. Initially, immune checkpoint inhibitors and targeted agents proved their worth in the treatment of advanced, unresectable melanoma patients. More recently, however, interest grew in combining both these therapeutic approaches in patients with BRAF mutant advanced melanoma. During ASCO 2020, results were presented of two clinical trials evaluating this strategy. Following the initial successes in the unresectable melanoma setting, immune checkpoint inhibition and targeted therapy were also evaluated as adjuvant therapy in patients with resected stage III melanoma. At ASCO 2020, updated results were presented of two pivotal trials in this setting, while other studies looked into the potential benefit of using immune checkpoint inhibitors as neoadjuvant therapies, rather than in the postoperative setting. In addition to this, immunotherapy also proved to have potential in the treatment of patients with mucosal melanoma, or leptomeningeal disease.

(BELG J MED ONCOL 2020;14(5):209-15)

Read more

Highlights in melanoma

BJMO - volume 13, issue 5, august 2019

B. Neyns MD, PhD

ASCO 2019 featured the presentation of several interesting studies in patients with metastatic melanoma. In addition to this, new data in the (neo)-adjuvant setting were presented.

Read more

BSMO Immunomanager program

BJMO - , issue ,

S. Aspeslagh , V. Kruse MD, PhD, E. De Langhe , P. Jacques , O. Malaise , D. Elewaut , B. Lauwerys , R. Wittoek , Y. Piette , B. Neyns MD, PhD

Immunotherapy has become a standard of care for patients with many different advanced solid tumors. However, boosting the immune system can induce immune related side effects, referred to as “immune-related adverse events” (irAEs). Because oncologists are not always familiar with these inflammatory autoimmune syndromes, the BSMO immunotaskforce has launched the immunomanager website which summarizes the treatment options for the most frequent irAEs including endocrine (e.g. hypo- and hyperthyroidism), digestive (e.g. colitis), pneumological (e.g. pneumonitis), dermatological and other types of irAEs. In the near future, the BSMO immunotaskforce plans to review these recommendations with Belgian organ specialists and their associations. We believe that through collaborations between organ specialists and oncologists we will be able to establish better recommendations, resulting in a better outcome for cancer patients who develop an irAE during immunotherapy.

Read more

Immunotherapy Highlights

BJMO - volume 12, issue 4, august 2018

B. Neyns MD, PhD, G. Awada MD, J. K. Schwarze

This article will summarize the key data in the field of immunotherapy presented during the 2018 annual meeting of the American Society of Clinical Oncology (ASCO).

Read more

BSMO Immunomanager program

BJMO - volume 12, issue 9, february 2018

S. Aspeslagh , V. Kruse MD, PhD, E. De Langhe , P. Jacques , O. Malaise , D. Elewaut , B. Lauwerys , R. Wittoek , Y. Piette , B. Neyns MD, PhD

Immunotherapy has become a standard of care for patients with many different advanced solid tumors. However, boosting the immune system can induce immune related side effects, referred to as “immune-related adverse events” (irAEs). Because oncologists are not always familiar with these inflammatory autoimmune syndromes, the BSMO immunotaskforce has launched the immunomanager website which summarizes the treatment options for the most frequent irAEs including endocrine (e.g. hypo- and hyperthyroidism), digestive (e.g. colitis), pneumological (e.g. pneumonitis), dermatological and other types of irAEs. In the near future, the BSMO immunotaskforce plans to review these recommendations with Belgian organ specialists and their associations. We believe that through collaborations between organ specialists and oncologists we will be able to establish better recommendations, resulting in a better outcome for cancer patients who develop an irAE during immunotherapy.

Read more
X